Skip Ribbon Commands
Skip to main content
Sign In
Skip to main content Open accessibility information page
Alert
On January 16, 2024, Governor Phil Murphy signed the New Jersey Data Privacy Law, P.L. 2023, c. 266. The law went into effect on January 15, 2025. Please click on this Frequently Asked Questions link to learn more about the new law and your rights under it.
Alert
On January 8, 2024, Governor Murphy signed into law P.L. 2023, c. 237, which, among other things: amended the Contractors’ Business Registration Act (“CBRA,” formerly the “Contractors’ Registration Act”), N.J.S.A. 56:8-136 et seq., and created the “Home Improvement and Home Elevation Contractor Licensing Act,” N.J.S.A. 45:5AAA-1 et seq. For more information on the registration requirements for contractors and businesses under these laws, click here.
Alert
On July 10, 2024, Governor Murphy signed into law the Real Estate Consumer Protection Enhancement Act, P.L. 2024, c.32, which, among other things, requires sellers of residential property located in New Jersey to use the "Seller's Property Condition Disclosure Statement" ("Disclosure Statement," questions 1 through 108).

Additionally, on July 3, 2023, Governor Murphy signed into law P.L. 2023, c.93, which, among other things, requires sellers of all real property located in New Jersey to make certain additional disclosures concerning flood risks on the "Disclosure Statement." On July 15, 2024, the Division published a "Flood Risk Addendum" to the Disclosure Statement (questions 109 through 117), which includes the additional disclosures concerning flood risks.

As a result of these two laws, effective August 1, 2024:
  • Sellers of residential property must complete the Disclosure Statement (questions 1 through 108). A copy of the Disclosure Statement is available here; and
  • All sellers of real property, both residential and non-residential, must complete the Flood Risk Addendum to the Disclosure Statement (questions 109 through 117). A copy of the Flood Risk Addendum is available here.

The Division has created an instruction sheet with additional information regarding the use of these forms. The forms linked above supersede any forms previously posted by the Division, including, but not limited to, the "Amended Disclosure Statement" posted on December 21, 2023.

Press Release

​​​​​​​​​​​​​​For Immediate Release:
March 9, 2022    

Office of The Attorney General
Matthew J. Platkin, Acting Attorney General

Division of Consumer Affairs
Sean P. Neafsey, Acting Director
​​​​ For Further Information Contact:
Lisa Coryell, OAGpress@njoag.gov

Proposed Regulation – Board of Medical Examiners


NEWARK – To address the ongoing opioid epidemic and to reduce the risk of addiction, the State Board of Medical Examiners proposes to amend N.J.A.C. 13:35-7.6 to ensure that practitioners have a clear understanding of a patient's medical history, assess a patient's predilection for addiction, develop appropriate treatment objectives, and continually evaluate whether opioid therapy is providing clinically meaningful improvement in pain and function.

In addition, the Board proposes to amend N.J.A.C. 13:35-7.6 to implement P.L. 2021, c. 54, which establishes conditions that trigger the obligation to co-prescribe an opioid antidote. P.L. 2021, c. 54, provides that when a health care practitioner prescribes an opioid drug which is a controlled dangerous substance, the prescriber shall additionally prescribe an opioid antidote if any of the following conditions are present: (a) the patient has a history of substance use disorder; (b) the prescription for the opioid drug is for a daily dose of more than 90 morphine milligram equivalents; or (c) the patient holds a current, valid prescription for a benzodiazepine drug that is a Schedule III or Schedule IV controlled dangerous substance.

The proposed regulation and information on how to submit a comment by April 23, 2022, can be viewed here

###

 







Last Modified: 3/31/2022 9:56 AM